PRCT rises as Wall Street slips; investors look again at Aquablation
PROCEPT BioRobotics shares were slightly higher early Thursday, up 18 cents to $28.29. The stock was steadier than much of the medical-device group as Wall Street opened lower again with new jitters over oil and the Middle East. According to Reuters, the Dow, S&P 500 and Nasdaq all slipped at the open. Procept BioRobotics shares barely moved, but even a slight gain is notable for a stock still working to regain trust after a rough guidance cut earlier this year. The company, which most recently was valued around $1.60 billion, has to prove adoption of its Aquablation systems can fuel more consistent procedures, boost consumable sales, and slow its cash burn.